ClinicalTrials.gg
CompletedNCT05977647Updated Aug 20, 2025

Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi

A Phase 4 interventional study of Tamsulosin Oral Capsule in Ureteric Stone of Lower Third of Ureter, sponsored by Getz Pharma. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-20.

Sponsored by Getz Pharma · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

As a first treatment option for small-size ureteric stones, α-blockers are now being used for medical expulsive therapy (MET) instead of invasive procedures. There is high evidence of the therapeutic benefit of α-blockers in the treatment of Distal ureteric stone (DUS); also endorsed by international guidelines.

However, limited data is available worldwide, on the effect of silodosin to treat DUS. A multi-center study is needed to confirm the efficacy and safety of therapy.

Read the detailed description

A kidney stone is a crystal formed inside the kidney. It is one of the commonest conditions of kidney disease affecting 12% of the world's population. Out of 12% Ureteric stones, around 20% represent cases of urolithiasis, of which 70% are situated in the lower third of the ureter and are termed as 'Distal Ureteric Stones' (DUS). Kidney stone aggravates the risk of end-stage kidney disease and increases the risk of multiple complications. including chronic kidney disease hypertension, diabetes, and cardiovascular diseases. The commonest type of kidney stone is calcium oxalate, which is present in around 70 to 80% of the total reported cases of kidney stones.

There are multiple approaches to the management of ureteric stones, which has evolved over the last 20 years, specifically due to advancements in technology, use of ureteroscopy and shockwave lithotripsy (SWL) as minimally invasive treatment options. However, these interventions are quite expensive and may lead to multiple complications. According to the complication rate of minimally invasive interventions is 2.5%.

As a first treatment option for small-size ureteric stones, α-blockers are now being used for medical expulsive therapy (MET) instead of invasive procedures. As observed through two meta-analyses there is high evidence of the therapeutic benefit of α-blockers in the treatment of DUS seen to be 52% and 44% higher than those patients who have not received any treatment.

There is an endorsement of the use of a-blockers as a management option for ureteric stones by the American Urology Association (AUA) and the European Association of Urology. The α1A- adrenoceptors have proven to play an important effect in intervening contraction of the human ureter, induced by phenylephrine. Silodosin (selective α1-adrenoceptor blocker) in the human ureter was found more efficacious than Tamsulosin (1D-adrenoceptor blocker) in non-adrenaline-induced contractions.

However, limited data is available worldwide, on the effect of silodosin to treat DUS. To the best of our knowledge, there has been no study done on the use of silodosin as MET for DUS in the context of Pakistan. Therefore, this study will be able to provide meaningful data to find the efficacy and safety of silodosin in comparison to Tamsulosin as MET in ureteric stone.

02

Conditions studied

  • Ureteric Stone of Lower Third of Ureter
03

In context

Lead sponsor

Getz Pharma is the lead sponsor of 19 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults male and female aged 18 to 70 years
  • Patients who give
  • Stone located in the distal 1/3rd of ureter (Single, unilateral and radiopaque ureteral calculus 5 to 10 mm visible on the CT-KUB± X-ray KUB within the ureter
  • Serum creatinine level within the normal range (adult men, 0.74 to 1.35 mg/dL \& 0.59 to 1.04 mg/dL)
  • Ability to tolerate oral fluids and oral pain medication

Exclusion criteria

Exclusion Criteria:

  • Patients already taking an alpha-adrenergic antagonist medication for 4 weeks
  • Evidence of any other renal stone simultaneously present or at any location
  • Hydronephrosis Grade 3 (Moderate) \& Grade 4 (Severe) Patients with \<60 ml/min/1.73m2
  • Signs of infection including temperature >38ºC or Urinalysis with any of the following: Positive Leukocyte Esterase, Positive Nitrates, or White Blood Cell Count >5/hfp in the setting of a positive urine culture (defined as a single isolated bacterial species population of >100,000 CFU)
  • Patients with chronic pain already undergoing treatment with narcotic medications or drug abusers
  • Pregnant or lactating women
  • Patient suffering from urinary tract infection, ureteral surgery, and existing DJ stents.
  • Clinical jaundice
  • Any forms of anatomical obstructions in the urinary tract
  • The previously suffering from postural hypotension
  • Any other disease jeopardizing participation in trial and could lead to increase patient health risks
  • History of allergic reactions with the study drugs (Silodosin or Tamsulosin)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (actual)

Study arms

  • Active comparator
    Tamsulosin

    Patients with lower ureteric stone will be randomized through permuted block randomization equally into two group. 120 patients will be on tamsulosin 0.4 mg once daily, therapy will be given for a maximum of 4 weeks.

    Drug: Tamsulosin Oral Capsule

  • Active comparator
    Silodosin

    Patients with lower ureteric stone will be randomized through permuted block randomization equally into two group. 120 patients will be on Silodosin 8 mg once daily. Therapy will be given for a maximum of 4 weeks.

    Drug: Tamsulosin Oral Capsule

Interventions

  • Patient will be enrolled in one of study arm through randomization.

    Also known as: silodosin Oral Capsule

06

What researchers measure

Primary outcomes

  1. % of stone expulsion

    The primary outcome measure will be the passage of stone expulsion self-reported definitive passage of calculus or the first day of pain-free to 48 hours period with calculus absent of X - ray KUB.

    Time frame: 4 weeks

Secondary outcomes

  1. Time in days to stone expulsion

    Time in days to stone expulsion: Self-reported definitive passage of calculus or the first day of pain-free to 48 hours period with calculus absent of X - ray.

    Time frame: 4 weeks

  2. Frequency of pain reported by patients

    Patient will mark the number of episodes of pain in 24 hours on daily basis in patient dairy..

    Time frame: 4 weeks

  3. Change in intensity of pain

    Patient dairy will be provided to all the patients. Which will have pain log scale. They will self-report the intensity of pain (highest intensity) in 24 hours on daily basis. The pain scale ranges are mentioned below. 1. 0 means no pain 2. 1 to 2 means mild pain 3. 2 to 4 means moderate pain 4. 4 to 6 means severe pain 5. 6 to 8 means very severe pain 6. 8 to 10 means worst pain ever

    Time frame: 4 weeks

  4. Usage of analgesics

    The subject will be given a standardized pain medication (diclofenac sodium) prescription at their initial visit and will be asked to keep track of how much pain medication they used each day in patient's dairy. This information will be collected at every week on follow up visits.

    Time frame: 4 weeks

  5. Frequency of ER visits

    Patient will report if he/she had visited ER in last 24 hours on daily basis in patient's dairy along with the medication prescribed in ER.

    Time frame: 4 weeks

  6. Frequency of adverse events (Postural hypotension, retrograde ejaculation, etc.)

    Patient will be briefed about the known adverse events of study drugs. If any side effects is observed by the patient will be reported in patient dairy. If any unknown side effects happen that will also be reported in patient diary.

    Time frame: 4 weeks

07

Study locations

1 site
  • North west general hospital
    Peshawar, KPK, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in May 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2023
First posted
Aug 4, 2023
StartActual
Sep 1, 2024
Primary completionActual
May 30, 2025
CompletionActual
Jun 30, 2025
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05977647
Lead sponsor
Getz Pharma
Responsible party
Sponsor
First posted
Aug 4, 2023
Start date
Sep 1, 2024
Primary completion
May 30, 2025
Completion
Jun 30, 2025
Last update
Aug 20, 2025

Study contacts

Salman El Khalid, MBBS
principal investigator · The Kidney Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion